Mesmerise to collaborate with Mayo Clinic to Transform Medical Education and Healthcare Workforce Training
13.1.2025 23:10:00 CET | Business Wire | Press release
Mesmerise is proud to announce the creation of NeuRealities, Inc., a transformative company designed to revolutionize medical education and healthcare training. As part of a know-how agreement with Mayo Clinic, the new company seeks to leverage Mayo Clinic’s unparalleled clinical expertise and trusted knowledge with Mesmerise’s pioneering advancements in AI-powered spatial computing to set a new standard for excellence in immersive learning experiences.
NeuRealities aims to introduce an open-standards digital platform that redefines how healthcare professionals learn and train. By integrating hyper-realistic AI-enabled digital humans, adaptive immersive experiences, and dynamic content tailored to individual learners, the platform can address critical gaps in medical education. Its first initiative—CT training for radiologic technicians—delivers interactive, hands-on scenarios that simplify complex medical concepts, allowing the potential for training to be more efficient, accessible, and effective.
Built on an exclusive worldwide agreement, NeuRealities enables access to Mayo Clinic’s expertise, allowing the intelligent platform to scale trusted expertise and human potential to reach learners worldwide. This commitment to democratizing access to trusted medical education fosters a new era of personalized learning, empowering healthcare professionals to meet the demands of an evolving industry with confidence and competence.
NeuRealities exemplifies a vision to create pioneering digital experiences that break traditional patterns of knowledge delivery, offering scalable, transformative solutions for reimagining healthcare education. This collaborative venture paves the way for a future where trusted expertise is available to anyone, anywhere, empowering healthcare professionals to deliver excellence in care and innovation across the globe.
About The Mesmerise Group
Since 2016, The Mesmerise Group has partnered with Fortune 500 companies to deliver transformative brand experiences, training sessions, and events designed to empower the enterprise. The company was founded by Daglar Cizmeci and Andrew Hawken, who are recognized experts in AI and spatial computing technologies. Their mission is to unlock the potential of these technologies and manage the opportunities and risks they present. The Mesmerise Group is a global company headquartered in London with locations throughout the U.S.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113104722/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 09:00:00 CET | Press release
AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat
SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 08:50:00 CET | Press release
The agreement ensures Europe’s satellite-based augmentation continues enhancing navigation for aviation and other critical users and lowering emissions SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports mar
LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 08:30:00 CET | Press release
Key win in LTTS’ Mobility Segment across multiple vehicle technology domains L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and
SFI Health™ EMEA Announces the Launch in Poland of Equazen® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 08:00:00 CET | Press release
Equazen® Forte represents a strategic evolution of the brand, extending its clinically researched omega-3 based cognitive support product formulation beyond children to young adults and adults through pharmacies across Poland. SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changi
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 07:07:00 CET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom